Prostaglandin E1 (PGE1) relaxes trabecular smooth muscle by interacting with speci®c G-protein coupled receptors on human corpus cavernosum smooth muscle and increasing intracellular synthesis of cAMP. Misoprostol (Cytotec TM ), is an oral prostaglandin E analogue. The purpose of this study was to compare the functional activity of misoprostol with PGE1 in human corpus cavernosum and cultured human corpus cavernosum smooth muscle cells. Misoprostol, misoprostol free acid or PGE1 induced dose-dependent relaxations in strips of human corpus cavernosum. At concentrations greater than 10 76 M, tissue recontraction was observed with all three agents. This was abrogated by pretreatment with the thromboxane A2 receptor antagonist SQ29,548. From these observations, we conclude that misoprostol is activated by human corpus cavernosum in situ and relaxes phenylephrine-precontrated tissue strips in vitro. This relaxation response is mediated by the increased cAMP synthesis by these agents.
Introduction
Caverject TM (PGE1 for intracavernosal injection) was the ®rst Food and Drug Administration approved pharmacotherapeutic for the treatment of erectile dysfunction. 1 The labile nature of prostaglandins, in part, has dictated administration of these agents primarily intracavernosally; although intraurethral means have been introduced (MUSE TM ). 2 Attempts have been made to produce more stable formulations of PGE. These include PGE1aalpha cyclodextrin complex (EDEX TM aViridal TM ) 3 and topical PGE1 cream (Topiglan TM ). 4 The development of a stable, PGE1 agonist which could be administered orally may be of value in the treatment of erectile dysfunction either as a single medication or in combination with other agents which act through different pharmacologic pathways. Misoprostol, an orally administered PGE (EP) receptor agonist, was ®rst reported to inhibit gastric acid secretion in humans 5 and has been used successfully in the treatment of gastric ulcers. 6 Clinical trials have also been conducted using misoprostol as an abortifactant 7 and in treatment of peripheral vascular disease. 8 Prostanoids are autocoids synthesized primarily from arachadonic acid and include PGD2, PGE2, PGF2a, prostacyclin and thromboxane A (reviewed by Pierce et al). 9 Of these lipid vasoactive substances, PGD2, PGE2 and prostacyclin can induce smooth muscle relaxation, depending on the receptors present. 9 Prostaglandin E is the major relaxatory prostanoid in corpus cavernosum smooth muscle. 10 The proposed mechanism of vasodilation of smooth muscle by PGE1 is that PGE1 binds to G-protein coupled receptors, increasing cAMP synthesis and eventually resulting in the lowering of intracellular calcium levels. 11 The end result is a change in myosin light chain phosphorylationadephosphorylation favoring smooth muscle relaxation. 11 While misoprostol is an effective agent in the gastric mucosa in the prevention of ulcers in the presence of nonsteroidal, anti-in¯ammatory drugs, 6 it remains to be demonstrated if this compound is ef®cacious in the relaxation of penile corpus cavernosum smooth muscle. The goals of this study were to compare misoprostol activity with PGE1 in inducing relaxation in human corpus cavernosum and in inducing cAMP synthesis in human corpus cavernosum smooth muscle cells.
Methods

Dose responses of misoprostol and PGE1 in human corpus cavernosum
These studies were approved by the Institutional Review Boards at Boston University Medical Center, the Mayo Clinic and Foundation and the University of Massachusetts Medical Center. Human corpus cavernosum was obtained from six patients undergoing penile prosthesis insertion at time of surgery. Tissues were stretched to reach isometric tension and maximal contractile responses to 1 mM phenylephrine determined as previously described. 12, 13 In these experiments, both misoprostol and the misoprostol free acid were tested. We recorded relaxation dose responses to misoprostol (10 79 ±10 75 M, Biomol, Plymouth Meeting, PA), misoprostol free acid (10 79 ±10 75 M, Biomol, Plymouth Meeting, PA), and PGE1 (10 79 ±10 75 M, Cayman Chemical, Ann Arbor, MI). Dose responses were also determined in the presence of 10 mM SQ29548 (Cayman Chemical, Ann Arbor, MI), a thromboxane A2 receptor antagonist. 14 Misoprostol and PGE1 stimulation of human corpus cavernosum smooth muscle cell cAMP synthesis Human corpus cavernosum smooth muscle cells from four different patients were cultured as previously reported. 15 Cells at passage 2±3 were grown to con¯uence in six-well plates. Media was aspirated and replaced with fresh media. Cells were treated with 10 mM 3-isobutyl-1-methylxanthine (IBMX) for 15 min and then treated for 5 min with either misoprostol free acid (0.1, 1 and 10 mM) or PGE1 (0.1, 1 and 10 mM). The reaction was terminated by quickly aspirating the media and adding 1 ml of ice cold 1 N perchloric acid. The cells were scraped and processed for cAMP with a commercially available radioimmunoassay (Biomedical technologies, Stoughton, MA), as described previously. 12 
Results
Misoprostol, misoprostol free acid and PGE1 induced dose-dependent relaxations in phenylephrine pre-contracted human corpus cavernosum in organ baths in vitro (Figure 1 ). The order of potency was PGE1 b misoprostol misoprostol free acid. Prostaglandin E1 at concentrations above 10 76 M induced dose-dependent contractions in human corpus (B) Effects of misoprostol free acid on relaxation of phenylephrine-precontracted human corpus cavernosum. Dose response of misoprostol free acid on phenylephrine-precontracted human corpus cavernosum. Data represent treatment in the absence (triangles) or presence (squares) of 10 mM SQ29548. n 6. Error bars represent standard error of the mean. C) Effects of PGE1 on relaxation of phenylephrine-precontracted human corpus cavernosum. Data represent treatment in the absence (triangles) or presence (squares) of 10 mM SQ29548. n 6. Error bars represent standard error of the mean.
Misoprostol relaxation of human corpus cavernosum RB Moreland et al cavernosum ( Figure 1C ). This effect was much more pronounced in misoprostol-treated corpus cavernosum ( Figure 1A and B), with the ®nal contraction of the tissue exceeding that observed with PGE1, particularly for misoprostol free acid. Pretreatment of smooth muscle strips with the thromboxane A2 receptor antagonist SQ29548 (10 mM) before the dose responses abrogated misoprostol ( Figure 1A ) or PGE1-induced recontraction of human corpus cavernosum ( Figure 1C) . Further, the inclusion of SQ29548 enhanced the relaxation of phenylephrine precontracted human corpus cavernosum to increasing doses of misoprostol and misoprostol free acid ( Figure 1B) to the extent observed with PGE1 in the presence of SQ29548. Treatment of human corpus cavernosum smooth muscle cells in culture with PGE1 or misoprostol free acid resulted in a dose-dependent increase in cAMP synthesis (Figure 2 ). Prostaglandin E1 was more effective than misoprostol free acid in inducing cAMP synthesis.
Discussion
Pharmacotherapy of erectile dysfunction began with injectable vasoactive substances and has progressed to the use of oral, systemic agents such as sildena®l citrate. 16 There is a need for new pharmacotherapeutics which can be administered orally with minimal side effects but ef®cacious in a wider spectrum of patients including those with an impaired nitric oxide system (for example, diabetics and radical prostatectomy patients, see ref. 16 ). While injectable PGE1 is reported to be effective in a wide spectrum of patients, 17 its use is hampered by the route of administration. Oral pharmacotherapy by its systemic nature, is subject to increased side effects. Prostaglandins are rapidly metabolised by the lung. 18 Hence, the ef®cacy of oral PGE1 may be complicated by rapid metabolism or from side effects such as increased gastrointestinal mobility due to activity of PGE (EP) receptors in the small bowel. 19, 20 A recent trial of oral PGE1 at 30 mg three times a day noted few side effects but while tumescence developed, no rigid erections were observed. The authors noted a signi®cant improvement in nocturnal penile tumescence with oral PGE1 administration. 21 In this study we examined the effects of misoprostol on inducing relaxation of phenylephrine precontracted human corpus cavernosum in vitro and increasing cAMP synthesis in human corpus cavernosum smooth muscle cells in culture. Misoprostol is a methyl ester which requires hydrolysis for activity with PGE (EP) receptors. Misoprostol is activated by human corpus cavernosum in situ and relaxes phenylephrine pre-contracted human corpus cavernosum ( Figure 1A ). There was no signi®cant difference between the relaxation responses produced by misoprostol free acid (activated) and misoprostol ( Figures 1A and B) . This was attributed to hydrolysis of misoprostol by corpus cavernosum tissue during experimentation. The inclusion of the thromboxane receptor antagonist improved the ef®cacy of misoprostol-induced relaxation such that it was indistinguishable from that induced by PGE1. Both PGE1 and activated misoprostol (free acid) induce cAMP synthesis in cultured human corpus cavernosum smooth muscle cells although PGE1 shows a greater response than misoprostol. The increased synthesis of cAMP corroborates that misoprostol exerts it effects via EP2 andaor EP4 receptors on human corpus cavernosum smooth muscle cells. 12, 14 While misoprostol induces smooth muscle relaxation and may be a useful pharmacotherapeutic agent, its ef®cacy as an oral agent must be assessed in clinical trials. The EC 50 from this study appears to be comparable to that of PGE1 ( 5 6 10 77 M). The need for such high concentrations may preclude the use of this agent due to potential hypotensive, gastrointestinal or other side effects. The success of Cytotec TM (misoprostol) in the treatment of gastric ulcers 6 may be due to the route of administration and achieving optimal concentrations in the stomach. In conclusion, while misoprostol may be an effective agent in relaxing human corpus cavernosum in vitro, it remains to be demonstrated clinically if this agent will be effective orally in the treatment of erectile dysfunction with minimal side effects. 
